A deeply discounted, post-pivot biotech: blockbuster-grade HCC survival data plus dual-target CAR‑T optionality—balanced by brutal Phase 3 and funding binaries.
Overview
Tempest Therapeutics is a clinical-stage oncology company that has undergone a major strategic pivot: from primarily a small-molecule oncology developer to a dual-platform business spanning first-in-class metabolic modulators and next-generation engineered cell therapies. The company’s scientific thesis targets two persistent shortcomings of modern immuno-oncology—tumor metabolic adaptation and immune suppression within the tumor microenvironment—while its 2026 acquisition of dual-targeting CAR‑T assets meaningfully broadened the pipeline into hematologic malignancies and select solid tumors. With no product revenue, Tempest relies on capital markets plus capital-efficient external funding, including a China partnership (Novatim) that funds development of lead CAR‑T candidate TPST‑2003 in-territory and provides clinical data that may de-risk Tempest’s planned U.S. registrational strategy. Non-dilutive support (e.g., NCI funding for TPST‑1495 in FAP) further reduces cash burn. The lead small-molecule asset amezalpat (TPST‑1120), a first-in-class PPARα antagonist, produced an unusually strong randomized Phase 1b/2 signal in first-line HCC when added to atezolizumab/bevacizumab—median OS 21 vs 15 months—supporting Phase 3 readiness and global regulatory alignment. The lead CAR‑T asset TPST‑2003 targets rr multiple myeloma, particularly extramedullary disease, using dual CD19/BCMA targeting to reduce antigen-escape relapse risk, with highly encouraging China-generated response durability. Tempest’s opportunity is outsized relative to its micro-cap valuation, but remains dominated by pivotal-trial and financing binaries.